What does the evidence say about Hibiscus Cardiometabolic Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Hibiscus Cardiometabolic Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - This systematic review and meta-analysis aimed to evaluate the effects of LC extract supplementation on key cardiometabolic risk factors in adults. [Xu S (2026); evidence level 1] - LC supplementation significantly reduced body weight (WMD: -2.09 kg), BMI (WMD: -0.70 kg/m²), fat mass (WMD: -0.62%), total cholesterol (WMD: -9.06 mg/dL), systolic blood pressure (WMD: -8.59 mmHg), and diastolic blood pressure (WMD: -3.73 mmHg) as well as increased levels of HDL-C (WMD: +2.10 mg/dL). [Xu S (2026); evidence level 1] - No significant effects were found for glycemic markers and other lipid profiles. [Xu S (2026); evidence level 1] - Background Cardiometabolic disorders are a growing public health concern worldwide. [Xu S (2026); evidence level 1] - This study assessed 8-week changes in Atherogenic and triglyceride-glucose indices (AIP and TyG) after the consumption of a Hibiscus-inulin (HIB-INU) beverage and tested whether baseline risk modified these effects. [Mendivil EJ (2025); evidence level 2] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.